Cerebral Oximetry in the Neonatal Intensive Care Unit: Discussion of Two Contradicting Study Results (SafeBoosC-II, SafeBoosC-III)
- PMID: 39400797
- DOI: 10.1007/978-3-031-67458-7_7
Cerebral Oximetry in the Neonatal Intensive Care Unit: Discussion of Two Contradicting Study Results (SafeBoosC-II, SafeBoosC-III)
Abstract
Recently, the usefulness of near-infrared spectroscopy-based cerebral oximetry in extremely preterm infants to prevent death or severe brain injury was evaluated in a study called SafeBoosC-III (N = 1601). In this study, the incidence of both outcomes was similar between the cerebral oximetry and the control group. In a previous smaller study called SafeBoosC-II (N = 166), there was a borderline significant advantage for cerebral oximetry. There is therefore a highly significant (p = 0.010) difference between the two outcomes. What could be the reason for the difference? One major difference was that many centres were not familiar with cerebral oximeters in the new study compared with the old study. This could be a reason for the discrepancy. We conclude that cerebral oximetry should not be disregarded as a method of neuromonitoring in neonatology.
Keywords: Brain injury; Cerebral oximetry; Death; Near infrared spectroscopy; Preterm infants.
© 2024. Oxygen Transport to Tissue International.
Similar articles
-
A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial.Trials. 2013 May 1;14:120. doi: 10.1186/1745-6215-14-120. Trials. 2013. PMID: 23782447 Free PMC article. Clinical Trial.
-
Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial.Trials. 2023 Oct 7;24(1):653. doi: 10.1186/s13063-023-07653-x. Trials. 2023. PMID: 37805539 Free PMC article.
-
Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants.Trials. 2019 Dec 19;20(1):746. doi: 10.1186/s13063-019-3756-y. Trials. 2019. PMID: 31856902 Free PMC article.
-
Current research suggests that the future looks brighter for cerebral oxygenation monitoring in preterm infants.Acta Paediatr. 2015 Mar;104(3):225-31. doi: 10.1111/apa.12906. Epub 2015 Jan 29. Acta Paediatr. 2015. PMID: 25557591 Review.
-
NIRS in the fetal to neonatal transition and immediate postnatal period.Semin Fetal Neonatal Med. 2020 Apr;25(2):101079. doi: 10.1016/j.siny.2020.101079. Epub 2020 Jan 16. Semin Fetal Neonatal Med. 2020. PMID: 32007425 Review.
References
-
- Rasmussen MI et al (2023) Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial. Trials 24(1)
-
- SafeBoosC-III (2023) Available from: https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/d...
MeSH terms
Substances
LinkOut - more resources
Full Text Sources